[go: up one dir, main page]

WO2009071095A3 - Prevention of hyperthermia subsequent to hypothermia treatment of ischemia - Google Patents

Prevention of hyperthermia subsequent to hypothermia treatment of ischemia Download PDF

Info

Publication number
WO2009071095A3
WO2009071095A3 PCT/DK2008/050293 DK2008050293W WO2009071095A3 WO 2009071095 A3 WO2009071095 A3 WO 2009071095A3 DK 2008050293 W DK2008050293 W DK 2008050293W WO 2009071095 A3 WO2009071095 A3 WO 2009071095A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypothermia
subsequent
hyperthermia
prevention
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2008/050293
Other languages
French (fr)
Other versions
WO2009071095A2 (en
Inventor
Jacob Gotfredsen
Uno Jakob Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROKEY AS
Original Assignee
NEUROKEY AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROKEY AS filed Critical NEUROKEY AS
Publication of WO2009071095A2 publication Critical patent/WO2009071095A2/en
Publication of WO2009071095A3 publication Critical patent/WO2009071095A3/en
Priority to PCT/DK2009/050196 priority Critical patent/WO2010015260A2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the prevention of hyperthermia or overshooting of normothermia during re-warming, subsequent to induction of hypothermia in humans, by the administration of at least one anti-pyretic compound of the present invention including but not limited to NSAIDS and acetaminophens, and/or administering at least one hypothermia inducing compound, wherein said hypothermia inducing compound is administered in decreasing dosages of said hypothermia inducing compound for a predetermined period, thereby reducing or preventing hyperthermia during re-warming, subsequent to medical or physical /mechanical hypothermia therapy.
PCT/DK2008/050293 2007-12-05 2008-12-05 Prevention of hyperthermia subsequent to hypothermia treatment of ischemia Ceased WO2009071095A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050196 WO2010015260A2 (en) 2008-08-07 2009-08-07 Administration by infusion for the treatment of ischemic effects

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DKPA200701743 2007-12-05
DKPA200701742 2007-12-05
DKPA200701743 2007-12-05
DKPA200701742 2007-12-05
DKPA200800716 2008-05-23
DKPA200800716 2008-05-23
DKPA200801079 2008-08-07
DKPA200801079 2008-08-07
DKPA200801105 2008-08-15
DKPA200801105 2008-08-15
DKPA200801337 2008-09-26
DKPA200801337 2008-09-26

Publications (2)

Publication Number Publication Date
WO2009071095A2 WO2009071095A2 (en) 2009-06-11
WO2009071095A3 true WO2009071095A3 (en) 2009-07-23

Family

ID=40671024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050293 Ceased WO2009071095A2 (en) 2007-12-05 2008-12-05 Prevention of hyperthermia subsequent to hypothermia treatment of ischemia

Country Status (1)

Country Link
WO (1) WO2009071095A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155300A1 (en) 2007-04-05 2010-02-24 Velomedix, Inc Automated therapy system and method
CA2693774A1 (en) 2007-07-09 2009-01-15 Velomedix, Inc. Hypothermia devices and methods
WO2009124551A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
WO2009124553A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
US9622670B2 (en) 2010-07-09 2017-04-18 Potrero Medical, Inc. Method and apparatus for pressure measurement
EP3732994B1 (en) 2013-02-08 2022-11-09 General Mills, Inc. Reduced sodium food products
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
WO2017055438A1 (en) * 2015-09-30 2017-04-06 SEIRATHERM GmbH Temperature adjustment infusion system and method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BABCOCK A M ET AL: "Neurotensin-induced hypothermia prevents hippocampal neuronal damage and increased locomotor activity in ischemic gerbils", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 32, no. 4, 1 January 1993 (1993-01-01), pages 373 - 378, XP024560973, ISSN: 0361-9230, [retrieved on 19930101] *
COIMBRA CICERO ET AL: "Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug: Evidence for chronic encephalopathic processes following ischemia", STROKE, vol. 27, no. 9, 1996, pages 1578 - 1585, XP009117623, ISSN: 0039-2499 *
KASNER SCOTT E ET AL: "Acetaminophen for altering body temperature in acute stroke: A randomized clinical trial", STROKE, vol. 33, no. 1, January 2002 (2002-01-01), pages 130 - 135, XP002530240, ISSN: 0039-2499 *
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 *
PEGORINI S ET AL: "Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS, vol. 144, 1 January 2005 (2005-01-01), pages 727 - 735, XP007904383, ISSN: 0007-1188 *
STEVENS T ET AL: "Effect of a standardized rewarming protocol and acetaminophen on core temperature after coronary artery bypass.", AMERICAN JOURNAL OF CRITICAL CARE : AN OFFICIAL PUBLICATION, AMERICAN ASSOCIATION OF CRITICAL-CARE NURSES MAY 1995, vol. 4, no. 3, May 1995 (1995-05-01), pages 189 - 197, XP009117593, ISSN: 1062-3264 *

Also Published As

Publication number Publication date
WO2009071095A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2009071095A3 (en) Prevention of hyperthermia subsequent to hypothermia treatment of ischemia
JP2013522303A5 (en)
WO2011016881A3 (en) An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
FI4212152T3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2013541583A5 (en)
CN111989095A (en) Methods of preventing or treating side effects of tumor therapy
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
HK1255584A1 (en) Combination therapy using acamprosate and d-cycloserine
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2011500589A5 (en)
PT1670489E (en) Use of xenon with hypothermia for treating neonatal asphyxia
BR112014032578A2 (en) active ingredient release form
WO2012163088A3 (en) Medicine for treating kidney and heart disease and the uses thereof
EA201170970A1 (en) DEFERIPRON APPLICATION FOR TREATMENT AND PREVENTION OF EYE DISEASES ASSOCIATED WITH IRON
CN104173434A (en) Traditional Chinese medicine for treating heatstroke
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
NZ599227A (en) Therapeutic agent for chronic pain
CN103372109A (en) Outer application drug for treating scabies
CN106266035A (en) A kind of formula controlling the stagnant food stagnation of harmony
MXPA05008543A (en) Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia.
CN104474052B (en) A kind of compound spirit treating eczema
Salvetti et al. Therapeutic implications of recent megatrials: in favor of old drugs
Ebell Effective topical treatments for nongenital warts
HK1225969A1 (en) Treatment of crohn's disease using low doses of laquinimod

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856460

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06.09.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08856460

Country of ref document: EP

Kind code of ref document: A2